Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Post-ERCP Pancreatitis by Indomethacin Vs Diclofenac

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-90 years old patients planned to undergo ERCP~Exclusion Criteria:~* Allergy to NSAIDs~* The administration of NSAIDs within 7 days~* Not suitable for NSAIDs administration (gastrointestinal hemorrhage within 4 weeks, renal dysfunction \[Cr \>1.4mg/dl=120umol/l\]; presence of coagulopathy before the procedure)~* Previous biliary sphincterotomy and papillary large balloon dilation~* Acute pancreatitis within 3 days before ERCP~* Hemodynamical instability~* Pregnancy or lactation~* Unable to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- diclofenac group (Type: EXPERIMENTAL): Patients without contraindications in diclofenac group received 100mg rectal diclofenac 30 mins before ERCP procedure.
- Indomethacin group (Type: ACTIVE_COMPARATOR): Patients without contraindications in indomethacin group received 100mg rectal indomethacin 30 mins before ERCP procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).